Publication - Abstract
Aug 11, 2020
Journal of Controlled Release
siRNA and mRNA structures were separated from the ChriST mRNA by RNase H-mediated cleavage of RNA/DNA ...
February 11, 2021
RNA therapeutics have high potential that is yet to be fully realized, largely due to challenges involved in the appropriate delivery to target cells. Extracellular vesicles (EVs) are lipid bound nanoparticles released by cells of all types and possess numerous features that may help overcome this hurdle and have emerged as a promising RNA delivery vehicle candidate. Despite extensive research into the engineering of EVs for RNA delivery, it remains unclear how the intrinsic RNA delivery efficiency of EVs compares to currently used synthetic RNA delivery vehicles. Using a novel CRISPR/Cas9-based RNA transfer reporter system, we compared the delivery efficiency of EVs to clinically approved state-of-the-art DLin-MC3-DMA lipid nanoparticles and several in vitro transfection reagents. We found that EVs delivered RNA several orders of magnitude more efficiently than these synthetic systems. This finding supports the continued research into EVs as potential RNA delivery vehicles.
Publication - Abstract
Aug 11, 2020
Journal of Controlled Release
siRNA and mRNA structures were separated from the ChriST mRNA by RNase H-mediated cleavage of RNA/DNA ...
Publication - Abstract
Nov 16, 2014
Advances in Genetics
The discovery of RNA interference (RNAi) in mammalian cells has created a new class of therapeutics based on the reversible silencing of specific disease-causing genes.